Should I buy or sell Ginkgo Bioworks stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" DNA shares. View DNA analyst ratings or view top-rated stocks .

What is Ginkgo Bioworks' stock price target for 2024?

4 brokerages have issued 1 year target prices for Ginkgo Bioworks' shares. Their DNA share price targets range from $1.25 to $3.00. On average, they predict the company's share price to reach $2.25 in the next year. This suggests a possible upside of 59.5% from the stock's current price. View analysts price targets for DNA or view top-rated stocks among Wall Street analysts .

How have DNA shares performed in 2023?

Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA stock has decreased by 16.6% and is now trading at $1.4103. View the best growth stocks for 2023 here .

Are investors shorting Ginkgo Bioworks?

Ginkgo Bioworks saw a decline in short interest in November. As of November 15th, there was short interest totaling 222,910,000 shares, a decline of 5.5% from the October 31st total of 235,940,000 shares. Based on an average daily volume of 19,520,000 shares, the days-to-cover ratio is currently 11.4 days. Approximately 17.2% of the shares of the stock are short sold. View Ginkgo Bioworks' Short Interest .

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our DNA earnings forecast .

What ETFs hold Ginkgo Bioworks' stock?

ETFs with the largest weight of Ginkgo Bioworks (NYSE:DNA) stock in their portfolio include VegTech Plant-based Innovation & Climate ETF (EATV) , iShares Genomics Immunology and Healthcare ETF (IDNA) , ARK Genomic Revolution ETF (ARKG) , ARK Innovation ETF (ARKK) , Direxion Moonshot Innovators ETF (MOON) , WisdomTree BioRevolution Fund (WDNA) , IQ U.S. Mid Cap R&D Leaders ETF (MRND) and Range Cancer Therapeutics ETF (CNCR) .

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.38%), ARK Investment Management LLC (8.68%), Sumitomo Mitsui Trust Holdings Inc. (2.80%), Schroder Investment Management Group (0.35%), Charles Schwab Investment Management Inc. (0.35%) and Welch & Forbes LLC (0.33%). Insiders that own company stock include Barry Canton , Christian O Henry , Jason R Kelly , Marie E Fallon, Marijn E Dekkers , Mark E Dmytruk , Reshma P Shetty and Shyam Sankar. View institutional ownership trends .

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Ginkgo Bioworks Stock Price, News & Analysis (NYSE:DNA)

$1.39

-0.05 (-3.47%)

(As of 05:11 PM ET)

Compare

Today's Range: $1.39
▼
$1.55
50-Day Range: $1.26
▼
$1.83
52-Week Range: $1.12
▼
$2.55

Volume: 20.76 million shs
Average Volume: 20.66 million shs
Market Capitalization: $2.94 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.25

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.75 Rating Score
Upside/Downside: 55.7% Upside
$2.25 Price Target
Short Interest: Bearish
17.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.17
Based on 12 Articles This Week
Insider Trading: Selling Shares
$22.72 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.37) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

648th out of 949 stocks

Biological Products, Except Diagnostic Industry

106th out of 161 stocks

2.9

Analyst's Opinion

Consensus Rating
Ginkgo Bioworks has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $2.25, Ginkgo Bioworks has a forecasted upside of 55.7% from its current price of $1.45.
Amount of Analyst Coverage
Ginkgo Bioworks has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
17.15% of the float of Ginkgo Bioworks has been sold short.
Short Interest Ratio / Days to Cover
Ginkgo Bioworks has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Ginkgo Bioworks has recently decreased by 5.52%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ginkgo Bioworks does not currently pay a dividend.
Dividend Growth
Ginkgo Bioworks does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DNA.

1.6

News and Social Media Coverage

News Sentiment
Ginkgo Bioworks has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Ginkgo Bioworks this week, compared to 4 articles on an average week.
Search Interest
Only 44 people have searched for DNA on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.
MarketBeat Follows
19 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is an increase of 12% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,720,197.00 in company stock.
Percentage Held by Insiders
15.05% of the stock of Ginkgo Bioworks is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.84% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ginkgo Bioworks is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ginkgo Bioworks is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ginkgo Bioworks has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications.

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets.

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award.

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022.

DNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DNA Stock News Headlines

November 28, 2023 | americanbankingnews.com

Insider Selling: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Major Shareholder Sells 37,650 Shares of Stock

November 28, 2023 | americanbankingnews.com

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Jason R. Kelly Sells 100,000 Shares

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 28, 2023 | americanbankingnews.com

Insider Selling: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Sells 100,000 Shares of Stock

November 27, 2023 | benzinga.com

Dutch ingredients Firm Vivici Partners With Ginkgo Bioworks For Alternative Protein Development

November 27, 2023 | finance.yahoo.com

Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins

November 26, 2023 | americanbankingnews.com

Ginkgo Bioworks (NYSE:DNA) Stock Price Up 5.8%

November 24, 2023 | msn.com

Where Will Ginkgo Bioworks Be in 5 Years?

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 22, 2023 | americanbankingnews.com

Molecular Partners (OTCMKTS:MLLCF) and Ginkgo Bioworks (NYSE:DNA) Critical Contrast

November 21, 2023 | seekingalpha.com

Ginkgo Bioworks: A Long Way To Go

November 20, 2023 | americanbankingnews.com

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Sells $154,000.00 in Stock

November 20, 2023 | americanbankingnews.com

Insider Selling: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Major Shareholder Sells $57,981.00 in Stock

November 17, 2023 | msn.com

Large language models learn to speak biology

November 16, 2023 | msn.com

Raymond James Downgrades Ginkgo Bioworks Holdings Inc - (DNA)

November 13, 2023 | finance.yahoo.com

Things Look Grim For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) After Today's Downgrade

November 12, 2023 | seekingalpha.com

Ginkgo Bioworks: More Revenue Issues

November 11, 2023 | uk.finance.yahoo.com

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2023 Earnings Call Transcript

November 10, 2023 | markets.businessinsider.com

Steven Mah Maintains Buy Rating for Ginkgo Bioworks Despite Lowered FY23 Guidance and Slow Growth

November 10, 2023 | msn.com

BTIG Downgrades Ginkgo Bioworks Holdings Inc - (DNA)

November 10, 2023 | finance.yahoo.com

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 30% But Not Lagging Industry On Growth Or Pricing

November 9, 2023 | msn.com

Why Ginkgo Bioworks Stock Was Plummeting on Thursday

November 9, 2023 | finance.yahoo.com

Foremost Farms Selects Ginkgo Bioworks to Develop Technology for Upcycling Dairy Co-products

November 8, 2023 | msn.com

Cathie Wood sinks nearly $2 million into falling tech stock

November 7, 2023 | benzinga.com

Preview: Ginkgo Bioworks Holdings's Earnings

November 1, 2023 | finance.yahoo.com

Ginkgo Bioworks Announces Date of Third Quarter 2023 Results Presentation

October 25, 2023 | seekingalpha.com

Porter's 5 Forces Suggest That Ginkgo Is A Buy

See More Headlines

Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:DNA
CUSIP: N/A
CIK: 1830214
Web: www.eagleequityptnrs.com
Phone: 877-442-5362
Fax: N/A
Employees: 1,292
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.25
High Stock Price Target: $3.00
Low Stock Price Target: $1.25
Potential Upside/Downside: +55.2%
Consensus Rating: Reduce
Rating Score (0-4): 1.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,104,930,000.00
Net Margins: -272.30%
Pretax Margin: -275.85%
Return on Equity: -36.36%
Return on Assets: -23.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.78
Quick Ratio: 6.78

Sales & Book Value

Annual Sales: $477.71 million
Price / Sales: 6.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.59 per share
Price / Book: 2.46

Miscellaneous

Outstanding Shares: 2,118,440,000
Free Float: 1,799,612,000
Market Cap: $3.07 billion
Optionable: Optionable
Beta: 1.31

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Jason Kelly (Age 42)
Founder, CEO & Director
Comp: $262.5k
Dr. Reshma P. Shetty (Age 42)
Founder, President, COO & Director
Comp: $262.5k
Mr. Mark E. Dmytruk (Age 52)
Chief Financial Officer
Comp: $465.25k
Mr. Thomas Knight Jr.
Founder
Mr. Austin Che
Founder, Head of Strategy & Treasurer
Mr. Bartholomew Canton
Founder, CTO & Secretary
Mr. Steven P. Coen CPA
Chief Accounting Officer
Karen Tepichin
General Counsel & Secretary
Ms. Anna Marie Wagner
Senior Vice President of Corporate Development
Ms. Samantha Sutton
Head of People

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" DNA shares.
View DNA analyst ratings or view top-rated stocks.
What is Ginkgo Bioworks' stock price target for 2024?: 4 brokerages have issued 1 year target prices for Ginkgo Bioworks' shares. Their DNA share price targets range from $1.25 to $3.00. On average, they predict the company's share price to reach $2.25 in the next year. This suggests a possible upside of 59.5% from the stock's current price.
View analysts price targets for DNA or view top-rated stocks among Wall Street analysts.
How have DNA shares performed in 2023?: Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA stock has decreased by 16.6% and is now trading at $1.4103.
View the best growth stocks for 2023 here.
Are investors shorting Ginkgo Bioworks?: Ginkgo Bioworks saw a decline in short interest in November. As of November 15th, there was short interest totaling 222,910,000 shares, a decline of 5.5% from the October 31st total of 235,940,000 shares. Based on an average daily volume of 19,520,000 shares, the days-to-cover ratio is currently 11.4 days. Approximately 17.2% of the shares of the stock are short sold.
View Ginkgo Bioworks' Short Interest.

When is Ginkgo Bioworks' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our DNA earnings forecast.
What ETFs hold Ginkgo Bioworks' stock?: ETFs with the largest weight of Ginkgo Bioworks (NYSE:DNA) stock in their portfolio include VegTech Plant-based Innovation & Climate ETF (EATV), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Direxion Moonshot Innovators ETF (MOON), WisdomTree BioRevolution Fund (WDNA), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and Range Cancer Therapeutics ETF (CNCR).
Who are Ginkgo Bioworks' major shareholders?: Ginkgo Bioworks' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.38%), ARK Investment Management LLC (8.68%), Sumitomo Mitsui Trust Holdings Inc. (2.80%), Schroder Investment Management Group (0.35%), Charles Schwab Investment Management Inc. (0.35%) and Welch & Forbes LLC (0.33%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends.
How do I buy shares of Ginkgo Bioworks?: Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ginkgo Bioworks Stock Price, News & Analysis (NYSE:DNA)

Ginkgo Bioworks MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ginkgo Bioworks Stock (NYSE:DNA)

DNA Stock Price History

DNA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DNA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™